Clinical Trial

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Study acronym: I-MAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-28; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Trial Details
NCT Number NCT06805617
Lead Sponsor Glenn J. Hanna
Collaborators: Summit Therapeutics
Conditions Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
Enrollment 35 participants
Start Date 2025-02-26
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-29